99 results about "Aureobacterium resistens" patented technology

The invention relates to bacillus amyloliquefaciens NCPSJ7 and further relates to an application of the strain in treating plant diseases, diseases before and after harvesting fruits and vegetables as well as in preventing food-borne pathogenic bacteria and putrefying bacteria. The strain is preserved in China Center for Type Culture Collection (CCTCC) on March 22, 2013, wherein the preservation number is CCTCC NO: M2013098 and the strain is named as bacillus amyloliquefaciens NCPSJ7. The thallus and fermentation liquor of the strain disclosed by the invention has the effects of treating plant diseases caused by plant pathogenic fungus including antagonistic peach root rotten disease, fusarium wilt of cucumber, botrytis cinerea, jujube anthracnose, pear black spot, pear blue mould, apple brown rot, apple altermaria leaf spot, watermelon fusarium wilt and the like, as well as diseases after harvesting fruits and vegetables and food-borne pathogenic bacteria and putrefying bacteria including antagonistic staphylococcus aureus, salmonella paratyphi A, vibrio parahaemolyticus, yeast and the like; moreover, the bacillus amyloliquefaciens is broad in spectrum and antibacterial and great in potential in developing novel, efficient and natural biological control and biological preservative and fresh-keeping preparation.

The invention discloses rhodotorula mucilaginosa and a fermentation culture substance and application thereof. The rhodotorula mucilaginosa is rhodotorula mucilaginosa TZR<2014>, and the preservation number is CCTCC NO:M2015574. Liquid state fermentation is conducted on the rhodotorula mucilaginosa by means of the fermentation culture medium, the biomass of fermentation liquor is 18 g/L, and the yield of carotenoid is 36 mg/L. The rhodotorula mucilaginosa has the effects of resisting staphylococcus aureus, gastric acid and cholate, and a solid fermentation substance of the rhodotorula mucilaginosa further contains pyruvic acid which has the functions of accelerating fat consumption, increasing the muscle yield, phagocytosing free radicals in bodies and inhibiting generation of the free radicals. Therefore, the rhodotorula mucilaginosa can be used for feed additives of livestock, poultry and aquatic animals and has a wide application prospect.

The invention discloses antibacterial soap which is characterized by comprising the following raw material components: 5-15% of coconut oil, 10-20% of palm oil, 3-10% of olive oil, 15-30% of beef tallow, 5-15% of sodium hydroxide, 2-8% of liquorice water extract, 1-3% of sodium dodecyl benzene sulfonate and 3-8% of titanium dioxide. The antibacterial soap obtained in the invention can be directlyapplied to the skin to effectively eliminate and kill bacteria on the skin and can resist staphylococcus aureus, Pseudomonas aeruginosa, escherichia coli and Candida albicans simultaneously.

The invention discloses a novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin with a strong antibacterial effect which is optimized by transforming the structure of bishydroxycoumarin compounds, and provides a preparation method thereof, wherein the chemical structure and crystal structure are obtained. The novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin has an antibacterial application value in preparation of a medicine resisting staphylococcus aureus (ATCC29213), methicillin-resistant staphylococcus aureus (MRSA, XJ7502), USA300 (LAC) and vancomycin-resistant staphylococcus aureus (Mu20ATCC700699).

The invention provides an application of a perylene tetracarboxylic dianhydride amidation compound in anti-staphylococcus aureus. The compound is simple to prepare, a perylene tetracarboxylic dianhydride compound and N,N-dimethylethylenediamine are used as raw materials, multiple steps are carried out, the compound can inhibit the growth of staphylococcus aureus, and the bacteriostasis circle of the compound is up to about 10 mm measured by the K-B method. The compound is subjected to 2-fold gradient dilution, and the measured minimum inhibitory concentration (MIC) against staphylococcus aureus is up to 6.25 mg/mL. The growth curve inhibition test shows that when a growth curve of the bacteria in the non-drug treatment group enters the logarithmic phase, a growth curve of the bacteria in the compound treatment group is still in the lag phase, and indicates that the compound can inhibit the division of staphylococcus aureus. The discovered compound in the future can be used for the control of staphylococcus aureus infection, can also be applied in the preparation of antibacterial biomaterials, and has certain application value.

The invention belongs to the technical field of genetic engineering and particularly relates to a bovine-derived anti-staphylococcus aureus genetic engineering single-chain antibody, a preparation method and application thereof. The single-chain antibody comprises a bovine antibody light-chain variable region VL, an intermediate junction peptide Linker and a bovine antibody heavy-chain variable regional VH, the connecting sequence thereof is VL-Linker-VH. The amino acid sequence of the bovine antibody light-chain variable region VL is shown as SEQ ID No: 1-8. The amino acid sequence of the bovine antibody heavy-chain variable region VH is shown as SEQ ID No: 9-16. The screened single-chain antibody (scFv) of positive clone is jointly applied to in-vitro and in-vivo inhibition staphylococcus aureus test and achieves ideal antibacterial effect. The single-chain antibody is used for preparing drugs for preventing and curing staphylococcus aureus bovine mastitis.

The invention relates to a preparation method of an antimicrobial bacterial cellulose material. The method comprises the following steps: adding an organosilicon quaternary ammonium salt into a solvent to obtain an organosilicon quaternary ammonium salt solution; and adding the organosilicon quaternary ammonium salt solution into a bacterial cellulose hydrogel, regulating the pH value to 2.0-7.0, carrying out stirring or oscillating reaction at 5-95 DEG C for 24-72 hours, and cleaning. The method is simple to operate and mild in conditions; and the grafting reaction occurs on the fiber surface, so that the grafting ratio is high. The graft-modified bacterial cellulose material has the advantages of bacterial resistance, protein adsorptivity, cell adhesion promotion characteristic, and specific pH responsivity and temperature responsivity. The antimicrobial bacterial cellulose material has excellent resistance to Staphylococcus aureus and other bacteria, is beneficial to adhesion and growth of the cells in the material, and enhances the application potential of the bacterial cellulose material in the fields of antimicrobial wound dressings, intelligent responsive drug-slow-release carriers, tissue engineering stent biomedicine and the like.

The invention belongs to the technical field of drugs produced by gene engineering in the biotechnological pharmacy industry and in particular relates to an antibacterial peptide. A primary structure of the antibacterial peptide is CLPLLISWIKRKRQQ-AGP-GSKKPVPIIYCNRRTGKCQRM. The newly designed antibacterial peptide simultaneously has the advantages of thanatin and melittin, not only has wide antibacterial spectrum but also can resist staphylococcus aureus and simultaneously avoids the disadvantage that melittin has strong hemolysis.

The invention discloses an antibody against staphylococcal enterotoxin B and application thereof. The heavy chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 5, SEQ ID No. 6 and SEQ ID No. 7, or is composed of CDR variants with equivalent functions; and light chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 9, SEQ ID No. 10 and SEQ ID No. 11, or is composed of CDR variants with equivalent functions. The antibody against staphylococcal enterotoxin B is capable of specifically binding with staphylococcal enterotoxin B or free enterotoxin B; and thus, the antibody can be used fortreating, preventing and diagnosing staphylococcus aureus infection. Therefore, the antibody against staphylococcal enterotoxin B will be an important research direction in the fields of "non-antibiotic" treatment of methicillin-resistant staphylococcus aureus infection and drug resistance development control.

The invention relates to a bovine-derived anti-staphylococcus aureus single-chain antibody. The antibody at least comprises a light chain variable region of an amino acid sequence which is represented in SEQ ID No.1, a heavy chain variable region of an amino acid sequence which is represented in SEQ ID No.2 and an intermediate connecting peptide which is located between the light chain variable region and the heavy chain variable region. The single-chain antibody can be specifically bound with staphylococcus aureus, has certain external neutralization activity and has good application prospects when used in related reagents or drugs for diagnosing, preventing and treating staphylococcus aureus bovine mastitis.

The invention relates to a benzopyran compound and application thereof. The benzopyran compound has a structure formula shown in a formula I. The application is the application of the compound in preparing a biological membrane medicine for resisting the staphylococcus aureus. The formula I is shown in the description, wherein R is 3-F, 4-F, 3,5-2F, 3,4,5-3F, 4-C1, 3,4-2C1, 3-Br, and 4-Br.

The invention discloses derivatives of naftifine hydrochloride as well as a preparation method and application thereof. The derivatives of naftifine hydrochloride are as shown in the formula I. By inhibiting expression and/or function of key catalyzing enzyme CrtN in a golden yellow pigment synthesis pathway and powerfully inhibiting synthesis of golden yellow pigment, virulence of bacteria can be lowered. The key catalyzing enzyme CrtN in the golden yellow pigment synthesis pathway can be taken as a drug acting target; and compounds capable of inhibiting expression and/or function of key catalyzing enzyme CrtN can be used for preparing anti-bacterial drug. The naftifine hydrochloride and the derivatives thereof can be used as inhibitors for catalyzing enzyme CrtN to powerfully inhibit synthesis of the golden yellow pigment, so that the virulence of staphylococcus aureus can be lowered, and therefore, the derivatives can be used for preparing the anti-bacterial drug, especially drug for resisting staphylococcus aureus infection.

The invention discloses a staphylococcus aureus enterotoxin A chemiluminiscence enzyme-linked immunoassay detection kit. The kit contains a monoclonal antibody resisting staphylococcus aureus enterotoxin A, horseradish peroxidase marked detection antibody solution resisting staphylococcus aureus enterotoxin A, staphylococcus aureus enterotoxin A serial standard solution, wrapping solution, washing solution, closing solution, chemiluminiscence solution and a chemiluminiscence enzyme-linked plate. The staphylococcus aureus enterotoxin A chemiluminiscence enzyme-linked immunoassay detection kit has the advantages of being strong in specificity, high in sensitivity and good in repeatability and is suitable for monitoring diseases and detecting staphylococcus aureus enterotoxin A in food and blood in rapid quantitative mode.

Diapers and wet wipes for cleansing of infants are made anti-bacterial by the inclusion therein of hop acid derivatives, specifically tetrahydroiso-alpha acid and hexahydro-beta acid. These compounds are effective to inhibit the growth of gram-positive bacteria, and specifically chosen to combat Staphylococcus aureus, a primary factor in toxic shock syndrome in infants.

The invention discloses an anti-Staphylococcus aureus alpha hemolysin monoclonal antibody and applications thereof, wherein the monoclonal antibody comprises a heavy chain and a light chain, the aminoacid sequence of the variable region of the heavy chain is represented by the sequence 2 in the sequence listing, and the amino acid sequence of the variable region of the light chain is representedby the sequence 4 in the sequence listing. According to the present invention, the full human source anti-alpha hemolysin monoclonal antibody is rapidly screened from the phage antibody library by using the alpha hemolysin as the target antigen; and the obtained monoclonal antibody is the completely-new antibody, has high affinity, can highly inhibit the hemolytic activity of alpha-hemolysin, canimprove the survival rate of mice infected with Staphylococcus aureus, and further has important application value in the prevention and control of Staphylococcus aureus.

The invention discloses a double-labeled gold nanorod probe, which is obtained by adding a urease solution into a suspension of the gold nanorods dropwise for mixing and swirling, adding anti-staphylococcus aureus antibody solution dropwise for mixing and swirling, and finally centrifuging and supernatant abandoning. The double-labeled probe converts the quantity signal of SA into a pH change of the solution by the catalytic action of urease and the specific recognition of IgY. A detection kit for staphylococcus aureus is provided at the same time, comprising the double-labeled gold nanorod probe, non-specific magnetic beads, saturated urea and phenolphthalein test paper, wherein the double-labeled gold nanorod probe is labeled with urease and anti-staphylococcus aureus antibody; the result is rapidly detected by phenolphthalein test paper from white to magenta. The invention has the advantages that the kit is easy to operate; the test result can be interpreted by naked eyes under natural light without any instrument; comparison with a standard color chart can be carried out to obtain semi-quantitative detection results; and the detection is fast and can be completed in 20 minutes.

The invention discloses an antibody for resisting staphylococcus aureus toxin and applications thereof, and relates to the technical field of antibodies. According to the antibody or a fragment thereof which is specifically combined with staphylococcus aureus toxin, the antibody or the fragment thereof can be specifically combined with a staphylococcus aureus gamma-hemolysin H1gB component, and can generate a cross reaction with other hemolysin components of the the hemolysin. The antibody comprises a variable region of heavy chain (VH) and a variable region of light chain (VL), wherein the variable region of heavy chain (VH) comprises the following CDR combination: VH-CDR1, VH-CDR2 and VH-CDR3, and the variable region of light chain (VL) comprises the following CDR combination: VL-CDR1, VL-CDR2 and VL-CDR3. The present invention can exert the effect of neutralizing, at least including neutralizing H1gB two-component toxin, thereby achieving the treatment of staphylococcus aureus infection alone or in combination with anti-staphylococcus aureus chemical drugs.

The invention discloses a staphylococcus aureus ITC (Inverse Transition Cycling) fusion protein which is a protein formed by fusing IsdB immunodominance fragments (IsdBid) and Trap as well as a ClfA immunodominance fragment N3 area (ClfAN3); an amino acid sequence of the fusion protein is as shown in SEQ ID NO.2. The invention further provides a coding gene, a preparation method and application of the fusion protein in preparing a vaccine for preventing staphylococcus aureus infection. The ITC fusion protein disclosed by the invention contains various antigens, and therefore, immune effect is good, protective effect of preventing staphylococcus aureus infection is improved; compared with the immune result of any of ClfA, IsdB and TraP, the ITC fusion protein immune effect is better than that of single protein; moreover, the ITC contains Trap with smaller molecular weight and has an immunodominance fragment with two antigens, so that peptide chain length is not lengthy, and therefore, the fusion protein is beneficial to in-vitro expression and has important value in developing and applying a novel vaccine for preventing staphylococcus aureus.

The invention discloses a chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C. The contents of the kit comprise a staphylococcal enterotoxin C-resistant monoclonal antibody, a horseradish peroxidase-marked staphylococcal enterotoxin C-resistant detection antibody solution, a staphylococcal enterotoxin C series standard solution, a coating solution, a sealing solution, a cleaning solution, a chemiluminescent solution and a chemiluminescent enzyme-linked plate. The kit has the characteristics of high specificity, sensitivity and repeatability, and is suitable for monitoring diseases and quickly and quantitatively detecting staphylococcal enterotoxin C in foods and blood.

The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.

The invention discloses a novel anti-staphylococcus aureus polyclonal antibody for treating staphylococcus aureus infection. The antibody is obtained by immunizing a New Zealand white rabbit with staphylococcus aureus MntC protein as a major immunizing antigen. The novel anti-staphylococcus aureus polyclonal antibody has an immune regulation effect and is capable of promoting the phagocytosis of the organism to the staphylococcus aureus so as to achieve the effect of treating the staphylococcus aureus infection.

The invention discloses an anti-staphylococcus aureus alpha-hemolysin single-chain antibody scFv2 or scFv46, further discloses an anti-staphylococcus aureus alpha-hemolysin recombinant antibody scFv2-Fc or scFv46-Fc containing the scFv2 or scFv46 and a human antibody constant region Fc segment amino acid sequence, and further discloses a universal expression vector sp-Fc/pcDNA3.1 of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The nucleic acid sequence of an encoding gene of the universal expression vector is shown in SEQ ID No:13. The invention further discloses a eukaryotic expression vector of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The eukaryotic expression vector is obtained by inserting the single-chain antibody into the sp-Fc/pcDNA3.1. The invention further discloses a recombinant expression vector sp-scFv2-Fc/pMH3 or sp-scFv46-Fc/pMH3.

The invention discloses an anti-Staphylococcus aureus eLtaS protein monoclonal neutralizing antibody E4-2, belonging to the technical field of preparation of antibodies for immunization. An antibody light/heavy chain variable region gene is cloned from the prepared eLtaS neutralizing monoclonal antibody E4-2, and can code correct mouse antibody variable regions. The light/heavy chain variable region gene based on the monoclonal antibody can be used for constructing and expressing multiple micromolecule gene engineering antibodies; and the polypeptide or protein coded on the basis of the gene can crosslink multiple biological activity molecules for preparing anti-Staphylococcus aureus infection drugs, and has wide application prospects.

The invention discloses a staphylococcus aureus capsular polysaccharide and protein conjugate and preparation method and application thereof. Salmonella typhimurium flagellin or polylysine salmonella typhimurium flagellin is taken as a carrier, and staphylococcus aureus capsular polysaccharide is subject to chemical modification, and then chemical coupling is carried out on the staphylococcus aureus capsular polysaccharide and the carrier protein. As the salmonella typhimurium flagellin and polylysine salmonella typhimurium flagellin have immunologic adjuvant function, the new formed conjugate can cause staphylococcus aureus capsular polysaccharide with extremely low immunogenicity to have higher immunogenicity, and the carrier protein plays the immunologic adjuvant function when in inoculation, so that specific immune response of immune animal to the staphylococcus aureus capsular polysaccharide is enhanced. The invention has wide application in preparation of vaccine resisting staphylococcus aureus infection.

The invention discloses a traditional Chinese medicine composition for adjusting female vaginal microecology. The traditional Chinese medicine composition comprises: be weight, 1 to 2 parts of licorice, 1 to 2 parts of clove, 1 to 2 parts of common cnidium fruit, 1 to 2 parts of pomegranate rind, 1 to 2 parts of Chinese gall, 1 to 2 parts of giant knotweed, 1 to 2 parts of Chinese magnoliavine fruit, 1 to 2 parts of anemone root, 1 to 2 parts of coptis root, 1 to 2 parts of amur corktree bark, 1 to 2 parts of aucklandia root and 1 to 2 parts of raw stemona root. The traditional Chinese medicine composition can be utilized directly for a female vagina to remove effectively pathogenic bacteria in the female vagina. The traditional Chinese medicine composition can kill staphylococcus aureus,staphylococcus epidermidis, streptococcus faecalis, escherichia coli, bacillus proteus, candida albicans, candida tropicalis, candida krusei and other candidas simultaneously.

The invention relates to a curcuminoid condensed aromatic amine Schiff base derivative and application thereof in preparation of antibacterial medicaments, belonging to the technical field of synthesized curcuminoid condensed 3, 5-diaromatic amine Schiff base derivatives and applications thereof. According to the technical scheme, the structure formula is shown in the description, wherein R is halogen on benzene ring para-position: fluorine, chlorine, bromine, and iodine. The curcuminoid condensed aromatic amine Schiff base derivative is used for preparing the antibacterial medicaments and used for resisting staphylococcus aureus and streptococcus. The curcuminoid condensed aromatic amine Schiff base derivative disclosed by the invention has an obvious inhibiting effect on the Staphylococcus aureus and the streptococcus; and compared with curcumin wich is a parent body, the curcuminoid condensed aromatic amine Schiff base derivative has the advantages that the antibacterial effect is better, the antibacterial effective time is longer, and the bioavailability and the antibacterial activity are improved.